KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of KVD824.
A leading sportswear company could be betting big on the growth of NFTs and the Metaverse, with several partnerships announced and hinted at over the last week.